Danmei Zhang, Klara Dorman, C Benedikt Westphalen, Michael Haas, Steffen Ormanns, Jens Neumann, Max Seidensticker, Jens Ricke, Enrico N De Toni, Frederick Klauschen, Hana Algül, Timo Reisländer, Stefan Boeck, Volker Heinemann
For decades, treatment of advanced biliary tract cancer (BTC) was confined to the use of chemotherapy. In recent years however, the number of therapeutic options available for patients with unresectable BTC have drastically increased, with immunotherapy and targeted treatment gradually joining the ranks of guideline-recommended treatment regimens. The aim of the present review is to summarise the current knowledge on unresectable BTC focusing on epidemiology, anatomical distribution and current strategies for systemic treatment...
April 12, 2024: European Journal of Cancer